Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Rivaroxaban

Research Leaders

5 sponsors active, led by University of Melbourne

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 4 (2)

Trial Status

Recruiting2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06650501Phase 4Recruiting

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

NCT06637332Phase 4Recruiting

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

NCT01212601CompletedPrimary

Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice

Showing all 3 trials

Research Network

Common Treatments

  • Rivaroxaban1
  • Apixaban1
  • Dabigatran1
  • Edoxaban1
  • Vancomycin1

Active Sponsors

  • University of Melbourne2
  • The Peter Doherty Institute for Infection and Immunity1
  • McGill University Health Centre/Research Institute of the McGill University Health Centre1
  • Todd C. Lee MD MPH FIDSA1
  • AstraZeneca1

Top Investigators

Related Conditions

  • Staphylococcus Aureus Endocarditis2
  • Staphylococcus Aureus Bacteremia2
  • S Aureus Bacteremia2
  • Staphylococcus Aureus Septicemia2
  • Staphylococcus Aureus Bloodstream Infection1

Activity Timeline